BIOMAB EGFR Injection BIOMAB EGFR contains Nimotuzumab, a humanized monoclonal antibody designed to selectively target and block the Epidermal Growth Factor Receptor (EGFR) expressed on cancer cell surfaces. Overexpression of EGFR fuels uncontrolled cell multiplication and tumor survival in solid malignancies. By binding to these receptors, the medication halts critical growth signaling pathways and signals the immune system to destroy tumor cells, offering targeted anti-cancer activity with a reduced risk of severe skin toxicities often seen with other anti-EGFR therapies.